Compare Adaptive Biotechnologies Corp (ADPT) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Rivian Automotive, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Rivian Automotive, Inc. trades at $16.59 (market cap $22.44B). The key difference: Rivian Automotive, Inc. is far larger — about 6.7× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | RIVN | |
|---|---|---|
Market Cap | $3.33B | $22.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $22.45 |
52-Week Low | $10.24 | $11.64 |
Enterprise Value | $3.19B | $24.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Rivian (RIVN) trades at $16.49, down 11.49% amid a 75 million share offering announced July 7, 2026, raising dilution concerns despite recent quarterly EPS beats. The stock shows a bullish technical signal with moving averages supporting upside, but RSI indicates overbought conditions. Revenue grew to $5.39B in 2025, yet net losses persist at -$3.65B, with cash flow negative but improving. Analyst consensus is mixed with a $21.29 price target.
Outlook remains challenged by high cash burn and dilution risks, but cost reductions and DOE loan potential offer long-term growth avenues. Investors face volatility from EV competition and execution hurdles, though institutional buy ratings suggest cautious optimism for profitability milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
